Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Rituximab. Found 9 abstracts

Costa LJ, Maddocks K, Epperla N, Reddy NM, Karmali R, Umyarova E, Bachanova V, Costa C, Glenn MJ, Chavez JC, Calzada O, Lansigan F, Nasheed H, Barta SK, Zhou Z, Jaglal M, Chhabra S, Hernandez-Ilizaliturri F, Xavier AC, Mehta A, Peker D, Forero-Torres A, Al-Mansour Z, Evens AM, Cohen JB, Flowers CR, Fenske TS, Hamadani M. Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies. American journal of hematology. 2017 Feb;92(2):161-70.   PMCID: PMC5549936
Schmier J, Ogden K, Nickman N, Halpern MT, Cifaldi M, Ganguli A, Bao Y, Garg V. Costs of Providing Infusion Therapy for Rheumatoid Arthritis in a Hospital-based Infusion Center Setting. Clinical therapeutics. 2017 Aug;39(8):1600-17.
Zahid MF, Khan N, Hashmi SK, Kizilbash SH, Barta SK. Central nervous system prophylaxis in diffuse large B-cell lymphoma. Eur J Haematol. 2016 Aug;97(2):108-20.
Dabaja BS, Vanderplas AM, Crosby-Thompson AL, Abel GA, Czuczman MS, Friedberg JW, Gordon LI, Kaminski M, Niland J, Millenson M, Nademanee AP, Zelenetz A, LaCasce AS, Rodriguez MA. Radiation for diffuse large B-cell lymphoma in the rituximab era: analysis of the National Comprehensive Cancer Network lymphoma outcomes project. Cancer. 2015 Apr;121(7):1032-9.   PMCID: PMC5531172
Kelly JL, Salles G, Goldman B, Fisher RI, Brice P, Press O, Casasnovas O, Maloney DG, Soubeyran P, Rimsza L, Haioun C, Xerri L, LeBlanc M, Tilly H, Friedberg JW. Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies. J Clin Oncol. 2015 May;33(13):1482-90.   PMCID: PMC4404425
Barta SK, Xue X, Wang D, Lee JY, Kaplan LD, Ribera JM, Oriol A, Spina M, Tirelli U, Boue F, Wilson WH, Wyen C, Dunleavy K, Noy A, Sparano JA. A new prognostic score for AIDS-related lymphomas in the rituximab-era. Haematologica. 2014 Nov;99(11):1731-7.   PMCID: 4222464
Evens AM, Smith MR, Lossos IS, Helenowski I, Millenson M, Winter JN, Rosen ST, Gordon LI. Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumour burden indolent non-Hodgkin lymphoma: a multicentre phase II study. Br J Haematol. 2014 Aug;166(4):514-20.
Murray JC, Aldeghaither D, Wang S, Nasto RE, Jablonski SA, Tang Y, Weiner LM. c-Abl modulates tumor cell sensitivity to antibody-dependent cellular cytotoxicity. Cancer Immunol Res. 2014 Dec;2(12):1186-98.   PMCID: 4258447
Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, Vanderplas A, Zelenetz AD, Abel GA, Rodriguez MA, Nademanee A, Kaminski MS, Czuczman MS, Millenson M, Niland J, Gascoyne RD, Connors JM, Friedberg JW, Winter JN. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014 Feb 06;123(6):837-42.   PMCID: PMC5527396
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Rituximab

Rituximab therapeutic use drug therapy Monoclonal Antibodies-Murine-Derived Middle Aged Female administration & dosage Male Treatment Outcome Antineoplastic Combined Chemotherapy Protocols mortality Adult Aged Large B-Cell Lymphoma-Diffuse adverse effects Prognosis Antineoplastic Agents Prospective Studies Disease Progression Cyclophosphamide diagnosis Doxorubicin Vincristine Monoclonal Antibodies Risk Factors 80 and over Aged Prednisone Follow-Up Studies Hematopoietic Stem Cell Transplantation Antibody-Dependent Cell Cytotoxicity Incidence Animal Disease Models prevention & control Non-Hodgkin Lymphoma Tumor Cell Line Tandem Mass Spectrometry Time Factors Viral Load Abatacept abatacept genetics antibodies central nervous system relapse analogs & derivatives drug effects myc therapeutic doxorubicin Rheumatoid Arthritis Economic Models rheumatoid Gene Knockdown Techniques methods AIDS-Related Lymphoma International Agencies Neoplastic Gene Expression Regulation Neoplasms prognosis Practice Guidelines as Topic and prednisone (R-CHOP) follicular lymphoma Antirheumatic Agents Cohort Studies RNA Interference Hospital Costs Survival Premedication cancer Kaplan-Meier Estimate Intravenous Infusions United States immunology hospital costs Pyrazines Genomics monoclonal radiotherapy Lymphoma Genes vincristine diffuse large B-cell lymphoma early stage Biomarkers treatment cyclophosphamide Liquid Chromatography Proto-Oncogene Proteins c-abl economics central nervous system involvement humanized Central Nervous System Neoplasms epidemiology Chemoradiotherapy Reproducibility of Results Survival Analysis pharmacology Gene Expression Profiling CD4 Lymphocyte Count Monoclonal Antibodies-Humanized Program Development blood Vitamin D Deficiency Disease-Free Survival rituximab radiation Vitamin D Non-Hodgkin Follicular Lymphoma Recurrence pathology Neoplasm Staging Bortezomib Survival Rate antagonists & inhibitors central nervous system Infliximab arthritis Boronic Acids prophylaxis Clinical Trials as Topic Home Infusion Therapy Cell Proliferation use Spinal Injections consolidation infliximab Proportional Hazards Models
Last updated on Thursday, April 02, 2020